New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint
Composite Efficacy Sustained at Late Follow-up Visit
Safety Profile Consistent with Meropenem